The estimated Net Worth of Adam Logal is at least $1.39 million dollars as of 9 May 2019. Mr Logal owns over 3,250 units of Opko Health Inc stock worth over $279,493 and over the last 17 years he sold OPK stock worth over $0. In addition, he makes $1,111,200 as Sr. VP & CFO at Opko Health Inc.
Sign up
Mr Logal OPK stock SEC Form 4 insiders trading
Mr has made over 13 trades of the Opko Health Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 3,250 units of OPK stock worth $6,630 on 9 May 2019.
The largest trade he's ever made was exercising 264,207 units of Opko Health Inc stock on 13 March 2017 worth over $282,701. On average, Mr trades about 23,237 units every 100 days since 2008. As of 9 May 2019 he still owns at least 179,162 units of Opko Health Inc stock.
You can see the complete history of Mr Logal stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Adam E. Logal biography
Adam E. Logal is the Sr. VP & CFO at Opko Health Inc.
What is the salary of Mr Logal?
As the Sr. VP & CFO of Opko Health Inc, the total compensation of Mr Logal at Opko Health Inc is $1,111,200. There are 3 executives at Opko Health Inc getting paid more, with Phillip Frost having the highest compensation of $1,405,200.
How old is Mr Logal?
Mr Logal is 43, he's been the Sr. VP & CFO of Opko Health Inc since . There are 20 older and 1 younger executives at Opko Health Inc. The oldest executive at Opko Health Inc is John Paganelli, 85, who is the Independent Director.
What's Mr Logal's mailing address?
Adam's mailing address filed with the SEC is 945, Concord Street, Framingham, Middlesex County, Massachusetts, 01701, United States.
Insiders trading at Opko Health Inc
Over the last 18 years, insiders at Opko Health Inc have traded over $862,245 worth of Opko Health Inc stock and bought 128,867,460 units worth $425,265,065 . The most active insiders traders include Phillip Md Et Al Frost Neva..., Phillip Md Et Al Frost Gamm... et Phillip Md Et Al Frost Gamm.... On average, Opko Health Inc executives and independent directors trade stock every 4 days with the average trade being worth of $142,696. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 23 May 2024, trading 100,000 units of OPK stock currently worth $127,000.
What does Opko Health Inc do?
opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig
What does Opko Health Inc's logo look like?
Complete history of Mr Logal stock trades at Opko Health Inc, VBI Vaccines et Xenetic Biosciences Inc
Opko Health Inc executives and stock owners
Opko Health Inc executives and other stock owners filed with the SEC include:
-
Phillip Frost,
Chairman of the Board, Chief Executive Officer -
Jane Hsiao,
Vice Chairman of the Board, Chief Technical Officer -
Steven Rubin,
Executive Vice President - Administration, Director -
Adam E. Logal,
Sr. VP & CFO -
Dr. Phillip Frost Ph.D.,
Chairman & CEO -
Adam Logal,
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer -
Dr. Jane H. Hsiao M.B.A., MBA, Ph.D.,
Vice Chairman & Chief Technical Officer -
Steven D. Rubin Esq., J.D.,
Exec. VP of Admin. & Director -
Richard Pfenniger,
Independent Director -
John Paganelli,
Independent Director -
Richard Krasno,
Independent Director -
Richard Lerner,
Independent Director -
Robert Fishel,
Independent Director -
Alice Yu,
Independent Director -
Yvonne Briggs,
Investor Relations -
Anthony Japour,
Independent Director -
Geoff Monk,
President of BioReference Laboratories -
Tony Cruz,
Chief Executive Officer, Transition Therapeutics, Inc -
Charles Bishop,
Chief Executive Officer of OPKO Renal -
Jon Cohen,
Director, Executive Chairman of BioReference Laboratories -
Dr. David Okrongly Ph.D.,
Pres of OPKO Diagnostics -
Jane Pine Wood Esq., J.D.,
Chief Legal Officer of Bio-Reference Laboratories -
Dr. Akhtar Ashfaq,
Sr. VP of Clinical R&D and Medical Affairs -
James DeMarco,
Sr. VP of Pharmaceutical Sales -
Dr. Arie Gutman,
Pres of API -
Alexis Borisy,
Director -
Phillip Md Et Al Frost Gamm...,
CEO & Chairman -
Gary J. Nabel,
Chief Innovation Officer -
Phillip Md Et Al Frost Neva...,
CEO & Chairman -
Phillip Md Et Al Frost,
CEO & Chairman -
Roger Md Medel,
-
Prem A Lachman,
-
Gamma Investment Trust Frost,
10% owner -
Subbarao V Uppaluri,
Senior VP- CFO -
Thomas E Beier,
Director -
Robert A Baron,
Director -
Michael Reich,
Director -
David A Eichler,
Director -
Dmitry Kolosov,
Director -
Md Pascal J Goldschmidt,,
Director -
Elias A. Zerhouni,
Vice Chairman and President